Status:
UNKNOWN
A Safety and Efficacy Study of Duvelisib in Relapsed/Refractory Follicular Lymphoma
Lead Sponsor:
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Conditions:
Follicular Lymphoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This is a phase 2 clinical trial to evaluate the safety and efficacy of duvelisib as a monotherapy in subjects diagnosed with follicular lymphoma (FL) that is relapsed or refractory to either chemothe...
Detailed Description
This is an open-label, single arm, multi-center clinical trial to evaluate the efficacy and safety of duvelisib administered to subjects who have been diagnosed with follicular lymphoma that is relaps...
Eligibility Criteria
Inclusion
- Subjects must have been fully informed and signed informed consent form.
- Subjects must be adults (\>/=18 years), male or female.
- Subjects who have been defined as FL by histologic or cytologic diagnosis, and must have relapsed or been refractory (at least two prior regimens for FL).
- Measurable disease with a lymph node or tumor mass ≥1.5 cm in at least one dimension by CT, PET/CT or MRI according to Lugano 2014 criteria.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
- Adequate renal and hepatic function.
- Women of childbearing potential must have a negative serum or urine β human chorionic gonadotropin (βhCG) pregnancy test.
- Willingness of male and female subjects who are not surgically sterile or postmenopausal to use medically acceptable methods of birth control for the duration of the study, including 30 days after the last dose of duvelisib.
Exclusion
- Grade 3B FL and/or clinical evidence of transformation to a more aggressive subtype of lymphoma.
- Known hypersensitivity to the study drug duvelisib or excipients.
- Previous treatment with a PI3K inhibitor or BTK inhibitor.
- Prior history of allogeneic hematopoietic stem cell transplant (HSCT).
- Prior chemotherapy, cancer immunosuppressive therapy, radiotherapy or other investigational agents within 4 weeks before the first dose of study drug.
- Symptomatic central nervous system (CNS) Lymphoma.
- Ongoing systemic bacterial, fungal, or viral infections at the time of initiation of study treatment.
- Human immunodeficiency virus (HIV) infection.
- Active cytomegalovirus (CMV) or Epstein-Barr virus (EBV) infection.
- Hepatitis B or hepatitis C Infection.
- History of stroke, unstable angina, or ventricular arrhythmia requiring medication or mechanical control within the last 6 months prior to first dose of study drug.
- Female subjects who are pregnant or breastfeeding.
Key Trial Info
Start Date :
December 18 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 31 2022
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT04707079
Start Date
December 18 2019
End Date
March 31 2022
Last Update
January 13 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shanghai Ruijin Hospital
Shanghai, Shanghai Municipality, China, 200020